行情

NBY

NBY

Novabay制药
AMEX

实时行情|Nasdaq Last Sale

0.8894
+0.0197
+2.27%
交易中 15:31 03/05 EST
开盘
0.8700
昨收
0.8697
最高
0.8950
最低
0.7851
成交量
134.08万
成交额
--
52周最高
1.940
52周最低
0.2400
市值
3,716.14万
市盈率(TTM)
-2.1672
分时
5日
1月
3月
1年
5年
美国传染病官员Fauci说2022年美国人可能仍会戴着口罩
-CNN
CNN · 02/21 14:29
Alpha Pro Tech,NovaBay制药股价低迷;美国民主党人计划增加刺激性的PPP资金$ 813.7B
-Reuters -Reuters 
Reuters -Reuters  · 02/09 15:26
NovaBay首席执行官致股东信
NovaBay Pharmaceuticals (NYSE:NBY) issued the following Letter to Stockholders: To My Fellow Stockholders: NovaBay Pharmaceuticals enters 2021 focused on growing sales of our high-quality, differentiated consumer
Benzinga · 02/08 11:50
Fauci说CDC可能建议戴两个口罩对抗病毒
-Reuters 
Reuters  · 02/02 14:59
Alpha Pro技术份额见交易量;拜登总统说“面具而不是疫苗”是抵御COVID-19的最佳选择
-Reuters -Reuters 
Reuters -Reuters  · 01/26 22:05
拜登订购戴面具的联邦财产
-Bloomberg
Bloomberg · 01/20 10:05
NovaBay Pharmaceuticals Expands Avenova's Geographic Reach to Australia with New Exclusive Distribution Agreement
NovaBay® Pharmaceuticals, Inc. (NYSE:NBY), a pharmaceutical company focusing on commercializing Avenova® for the eye care market, announces the signing of an agreement with Paragon Care Group Australia Pty Ltd
Benzinga · 2020/11/23 11:53
President-Elect Biden Says Discussed Nationwide Mask Mandate With State Governors
-Reuters-Reuters
Reuters-Reuters · 2020/11/19 21:22
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解NBY最新的财务预测,通过NBY每股收益,每股净资产,每股现金流等数据分析Novabay制药近期的经营情况,然后做出明智的投资选择。
分析师评级

2位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测NBY价格均价为2.625,最高价位3.500,最低价为1.750。
EPS
机构持股
总机构数: 20
机构持股: 64.76万
持股比例: 1.55%
总股本: 4,178.26万
类型机构数股数
增持
3
38.36万
建仓
7
17.45万
减持
6
9.77万
平仓
2
1.24万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+0.98%
制药与医学研究
+1.29%
高管信息
Non-Executive Chairman/Independent Director
Paul Freiman
President/Chief Executive Officer/Director/IR Contact Officer
Justin Hall
Chief Financial Officer/Treasurer
Andrew Jones
Controller
Wang Xu
Director
Xinzhou Li
Director
Mijia Wu
Independent Director
Swan Sit
Independent Director
Yenyou Zheng
暂无数据
NBY 简况
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox. Its Avenova with Neutrox removes debris from the skin on the eyelids and lashes without burning or stinging. It develops additional products containing Neutrox, including its NeutroPhase Skin and Wound Cleanser for wound care and CelleRx for the dermatology market. Its Aganocide compounds, led by auriclosene (NVC-422), are synthetic molecules with activity against bacteria, viruses and fungi. The Company's dermatology product includes CelleRx, a cleansing solution for post laser resurfacing, chemical peels and other cosmetic surgery procedures. Its wound care business includes the business of NeutroPhase product.

微牛提供NovaBay Pharmaceuticals, Inc.(AMEX-NBY)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的NBY股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易NBY股票基本功能。